ST3GAL5 and melanoma: We used lipidomics, CRISPR/Cas9 knockout screening, molecular and biophysical experiments, followed by xenograft melanoma animal studies to demonstrate that gomesins target the glycosphingolipid pathway via inhibition of the ST3GAL5 gene.